N@N

ADOLOR CORPORATION (NASDAQ:ADLR), Up By 5.03% ($0.10) From $1.990 After BUYINS.NET Report Predicted Strength Before Earnings

^{Published on 2011-07-01 13:20:34 - WOPRAI}
 

July 1, 2011 / M2 PRESSWIRE / BUYINS.NET, www.buyins.net , a provider of unique trading technologies, released a report on Thursday, June 30th 2011 stating that ADOLOR CORPORATION (NASDAQ:ADLR) was expected to be Up Before its earnings release. Click here to view the BUYINS.NET report: http://www.buyins.net/releases/?sym=adlr&id=175789

At the time this story was written, ADOLOR CORPORATION (NASDAQ:ADLR) is Up By 5.03% ($0.10) From $1.990 since the BUYINS.NET report was released.

The movement of stock prices in the days and weeks leading to and following earnings announcements may follow a predictable pattern. Most companies stock price histories show random or unpredictable movements around earnings dates. But some seem to repeat the same pattern quarter after quarter, year after year. The specific technology used to make these predictions is available for a low monthly fee at http://www.squeezetrigger.com/services/strat/mh.php

ADOLOR CORPORATION (NASDAQ:ADLR) - Adolor Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of prescription pain management products. Its product includes ENTEREG (alvimopan), a small molecule peripherally-acting mu-opioid receptor antagonist designed to block the adverse side effects of opioid analgesics on the gastrointestinal (GI) tract, as well as to accelerate upper and lower GI recovery following partial bowel resection surgery with primary anastomosis. The company also has various product candidates in clinical development, which include two delta opioid receptor agonist compounds, ADL5859 and ADL5747, under Phase IIa clinical trial in collaboration with Pfizer Inc. for the treatment of pain; and two opioid receptor antagonists, ADL7445 and ADL5945, which are entering into Phase II clinical trial to treat opioid bowel dysfunction, as well as other product candidates in preclinical development for treating moderate-to-severe pain and other central nervous system conditions. Adolor Corporation was founded in 1993 and is headquartered in Exton, Pennsylvania.

About BUYINS.NET

BUYINS.NET, www.buyins.net , monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market-maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:

REGULATORY & COMPLIANCE NEWS

Friction Factor -- market-maker surveillance system tracking market makers in all stocks to determine Price Friction and compliance with new "Fair Market-Making Requirements".

RegSHO Naked Shorts -- tracks EVERY failure to deliver in all US stocks and all Threshold Security Lists daily for which stocks have naked short positions.

INVESTMENTS & TRADING

SqueezeTrigger -- 28 billion cell database tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock.

Earnings Edge -- predicts probability, price move and length of move before and after all US stock earnings reports.

Seasonality -- predicts probability, price move and length of move based on exact time of year for all US stocks.

Group Trader -- tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups.

Pattern Scan -- automates tracking of every technical pattern and predicts next move in stocks.

GATS -- tracks and quantifies known trading strategies.

DISCLAIMER:

BUYINS.NET is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. ADOLOR CORPORATION (NASDAQ:ADLR) has not approved the statements made in this release. Please read our report and visit our web site, http://www.buyins.net, for complete risks and disclosures.

Contact: BUYINS.NET Thomas Ronk 800-715-9999 tom@buyins.net http://www.buyins.net